Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Innis

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Science Translational Medicine|September 26, 2014
Retraction of the letter: "Comment on 'CD4⁺ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy' "Robbert van der Most, Martine Wettendorff, Bruce Innis, et al.
Science Translational Medicine|June 27, 2014
Comment on "CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy"Robbert van der Most, Martine Wettendorff, Bruce Innis, et al.
Science Translational Medicine|August 8, 2014
Seeking help: B cells adapting to flu variabilityRobbert G van der Most, François P Roman, Bruce Innis, et al.
The Journal of Infectious Diseases|April 29, 2010
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adultsJoanne M Langley, Louise Frenette, Linda Ferguson, et al.
BMC Infectious Diseases|January 20, 2009
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete exampleJirí Beran, Veronika Wertzova, Karel Honegr, et al.
Vaccine|September 25, 2018
Corrigendum to "One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life" [Vaccine 36 (2018) 381-387]Ouzama Henry, Jerzy Brzostek, Hanna Czajka, et al.
Vaccine|December 12, 2017
One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of lifeOuzama Henry, Jerzy Brzostek, Hanna Czajka, et al.
The Pediatric Infectious Disease Journal|July 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging StudyJoon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, et al.
Vaccine|February 21, 2022
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global useErin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, et al.
Lancet (London, England)|November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Science Translational Medicine|September 26, 2014
Retraction of the letter: "Comment on 'CD4⁺ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy' "Robbert van der Most, Martine Wettendorff, Bruce Innis, et al.
Science Translational Medicine|June 27, 2014
Comment on "CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy"Robbert van der Most, Martine Wettendorff, Bruce Innis, et al.
Science Translational Medicine|August 8, 2014
Seeking help: B cells adapting to flu variabilityRobbert G van der Most, François P Roman, Bruce Innis, et al.
The Journal of Infectious Diseases|April 29, 2010
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adultsJoanne M Langley, Louise Frenette, Linda Ferguson, et al.
BMC Infectious Diseases|January 20, 2009
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete exampleJirí Beran, Veronika Wertzova, Karel Honegr, et al.
Vaccine|September 25, 2018
Corrigendum to "One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life" [Vaccine 36 (2018) 381-387]Ouzama Henry, Jerzy Brzostek, Hanna Czajka, et al.
Vaccine|December 12, 2017
One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of lifeOuzama Henry, Jerzy Brzostek, Hanna Czajka, et al.
The Pediatric Infectious Disease Journal|July 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging StudyJoon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, et al.
Vaccine|February 21, 2022
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global useErin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, et al.
Lancet (London, England)|November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
Pageof 2